These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4584519)

  • 21. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.
    Cui J; Ren B; Tong Y; Dai H; Zhang L
    Virulence; 2015; 6(4):362-71. PubMed ID: 26048362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis.
    Martins M; Lazzell AL; Lopez-Ribot JL; Henriques M; Oliveira R
    J Basic Microbiol; 2012 Aug; 52(4):487-91. PubMed ID: 22052380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candida albicans dimorphism as a therapeutic target.
    Jacobsen ID; Wilson D; Wächtler B; Brunke S; Naglik JR; Hube B
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):85-93. PubMed ID: 22149617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis.
    Navarathna DH; Hornby JM; Hoerrmann N; Parkhurst AM; Duhamel GE; Nickerson KW
    J Antimicrob Chemother; 2005 Dec; 56(6):1156-9. PubMed ID: 16239285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between virulence of Candida albicans mutants in mice and Galleria mellonella larvae.
    Brennan M; Thomas DY; Whiteway M; Kavanagh K
    FEMS Immunol Med Microbiol; 2002 Oct; 34(2):153-7. PubMed ID: 12381467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Candida albicans filamentation for antifungal drug development.
    Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
    Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic infection following intravenous inoculation of mice with Candida albicans int1 mutant strains.
    Bendel CM; Kinneberg KM; Jechorek RP; Gale CA; Erlandsen SL; Hostetter MK; Wells CL
    Mol Genet Metab; 1999 Aug; 67(4):343-51. PubMed ID: 10444345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal amphotericin B treatment of experimental fungal endophthalmitis.
    Axelrod AJ; Peyman GA
    Am J Ophthalmol; 1973 Oct; 76(4):584-8. PubMed ID: 4582798
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
    Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
    Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting Candida albicans Infection from the Perspective of C. albicans Virulence and Omics Approaches on Host-Pathogen Interaction: A Review.
    Chin VK; Lee TY; Rusliza B; Chong PP
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763544
    [No Abstract]   [Full Text] [Related]  

  • 31. Mouse intravenous challenge models and applications.
    MacCallum DM
    Methods Mol Biol; 2012; 845():499-509. PubMed ID: 22328398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of phenotypic switching on expression of virulence factors by Candida albicans causing candidiasis in diabetic patients.
    Antony G; Saralaya V; Gopalkrishna Bhat K; Shalini Shenoy M; Shivananda PG
    Rev Iberoam Micol; 2009 Sep; 26(3):202-5. PubMed ID: 19635443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of antibacterial drugs in mice with complex infection by Candida albicans and Escherichia coli.
    Ikeda T; Suegara N; Abe S; Yamaguchi H
    J Antibiot (Tokyo); 1999 Jun; 52(6):552-8. PubMed ID: 10470680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model.
    Fakhim H; Vaezi A; Dannaoui E; Chowdhary A; Nasiry D; Faeli L; Meis JF; Badali H
    Mycoses; 2018 Jun; 61(6):377-382. PubMed ID: 29460345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans.
    Navarathna DH; Hornby JM; Krishnan N; Parkhurst A; Duhamel GE; Nickerson KW
    Infect Immun; 2007 Apr; 75(4):1609-18. PubMed ID: 17283095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of cell-free thymus extracts on the course of experimental Candida albicans infection in mice.
    Mankowski ZT
    Mycopathol Mycol Appl; 1968 Dec; 36(3):247-56. PubMed ID: 5704125
    [No Abstract]   [Full Text] [Related]  

  • 37. Candida albicans VPS4 contributes differentially to epithelial and mucosal pathogenesis.
    Rane HS; Hardison S; Botelho C; Bernardo SM; Wormley F; Lee SA
    Virulence; 2014; 5(8):810-8. PubMed ID: 25483774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.
    Kadosh D; Najvar LK; Bocanegra R; Olivo M; Kirkpatrick WR; Wiederhold NP; Patterson TF
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6703-6708. PubMed ID: 27572393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathogenesis of candidiasis. (Studies on infections with protoplasts of Candida albicans)].
    Koch HA; Koch Y
    Dermatol Monatsschr; 1973 Apr; 159(4):398-9. PubMed ID: 4580137
    [No Abstract]   [Full Text] [Related]  

  • 40. SDH2 is involved in proper hypha formation and virulence in Candida albicans.
    Bi S; Lv QZ; Wang TT; Fuchs BB; Hu DD; Anastassopoulou CG; Desalermos A; Muhammed M; Wu CL; Jiang YY; Mylonakis E; Wang Y
    Future Microbiol; 2018 Aug; 13(10):1141-1156. PubMed ID: 30113213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.